MRPS33

Summary

MRPS33 (mitochondrial ribosomal protein S33, HGNC:16634) is a protein-coding gene on chromosome 7q34, encoding Small ribosomal subunit protein mS33 (Q9Y291).

Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein synthesis within the mitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of a small 28S subunit and a large 39S subunit. They have an estimated 75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another difference between mammalian mitoribosomes and prokaryotic ribosomes is that the latter contain a 5S rRNA. Among different species, the proteins comprising the mitoribosome differ greatly in sequence, and sometimes in biochemical properties, which prevents easy recognition by sequence homology. The 28S subunit of the mammalian mitoribosome may play a crucial and characteristic role in translation initiation. This gene encodes a 28S subunit protein that is one of the more highly conserved mitochondrial ribosomal proteins among mammals, Drosophila and C. elegans. Splice variants that differ in the 5’ UTR have been found for this gene; all variants encode the same protein. Pseudogenes corresponding to this gene are found on chromosomes 1q, 4p, 4q, and 20q

Source: NCBI Gene 51650 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 20 total — 1 pathogenic
• MANE Select transcript: NM_053035

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16634
Approved symbol	MRPS33
Name	mitochondrial ribosomal protein S33
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	CGI-139, mS33
Ensembl gene	ENSG00000090263
Ensembl biotype	protein_coding
OMIM	611993
Entrez	51650

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 15 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000324787, ENST00000393008, ENST00000467334, ENST00000469351, ENST00000472343, ENST00000484502, ENST00000485202, ENST00000496641, ENST00000496958, ENST00000893624, ENST00000893625, ENST00000893626, ENST00000918923, ENST00000918924, ENST00000918925, ENST00000918926, ENST00000918927, ENST00000966811, ENST00000966812

RefSeq mRNA: 2 — MANE Select: NM_053035 NM_016071, NM_053035

CCDS: CCDS5864

Canonical transcript exons

ENST00000324787 — 3 exons

Exon	Start	End
ENSE00001153630	141010419	141010660
ENSE00001266750	141014911	141014952
ENSE00003705040	141002610	141006535

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 98.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.8226 / max 310.2371, expressed in 1802 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86579	13.9531	1789
86578	9.8695	1734

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	98.10	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.71	gold quality
triceps brachii	UBERON:0001509	97.23	gold quality
rectum	UBERON:0001052	97.20	gold quality
diaphragm	UBERON:0001103	96.99	gold quality
heart left ventricle	UBERON:0002084	96.94	gold quality
cardiac ventricle	UBERON:0002082	96.86	gold quality
islet of Langerhans	UBERON:0000006	96.83	gold quality
biceps brachii	UBERON:0001507	96.82	gold quality
gastrocnemius	UBERON:0001388	96.70	gold quality
right atrium auricular region	UBERON:0006631	96.66	gold quality
apex of heart	UBERON:0002098	96.65	gold quality
body of pancreas	UBERON:0001150	96.61	gold quality
right adrenal gland	UBERON:0001233	96.54	gold quality
muscle of leg	UBERON:0001383	96.36	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.33	gold quality
right adrenal gland cortex	UBERON:0035827	96.25	gold quality
adrenal tissue	UBERON:0018303	96.22	gold quality
left adrenal gland	UBERON:0001234	96.19	gold quality
left adrenal gland cortex	UBERON:0035825	96.05	gold quality
transverse colon	UBERON:0001157	95.89	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.84	gold quality
heart right ventricle	UBERON:0002080	95.79	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.77	gold quality
gluteal muscle	UBERON:0002000	95.62	gold quality
heart	UBERON:0000948	95.57	gold quality
adrenal cortex	UBERON:0001235	95.52	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.39	gold quality
nucleus accumbens	UBERON:0001882	95.36	gold quality
adrenal gland	UBERON:0002369	95.28	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.61
E-MTAB-6379	no	1159.14
E-GEOD-100618	no	210.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting MRPS33, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-4326	98.97	67.63	962
HSA-MIR-12114	98.70	63.45	730
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-6867-3P	98.12	66.07	1305
HSA-MIR-124-5P	98.11	67.65	1095
HSA-MIR-4469	97.93	65.81	1319
HSA-MIR-4678	97.59	68.31	902
HSA-MIR-331-5P	96.59	67.94	705
HSA-MIR-6802-5P	94.94	65.95	366

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mrps33	ENSDARG00000020015
mus_musculus	Mrps33	ENSMUSG00000029918
rattus_norvegicus	Mrps33	ENSRNOG00000026528
drosophila_melanogaster	mRpS33	FBGN0038426
caenorhabditis_elegans		WBGENE00009013

Protein

Protein identifiers

Small ribosomal subunit protein mS33 — Q9Y291 (reviewed: Q9Y291)

Alternative names: 28S ribosomal protein S33, mitochondrial

All UniProt accessions (3): Q9Y291, A4D1T3, C9JBY7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Component of the mitochondrial small ribosomal subunit (mt-SSU). Mature mammalian 55S mitochondrial ribosomes consist of a small (28S) and a large (39S) subunit. The 28S small subunit contains a 12S ribosomal RNA (12S mt-rRNA) and 30 different proteins. The 39S large subunit contains a 16S rRNA (16S mt-rRNA), a copy of mitochondrial valine transfer RNA (mt-tRNA(Val)), which plays an integral structural role, and 52 different proteins.

Subcellular location. Mitochondrion.

Similarity. Belongs to the mitochondrion-specific ribosomal protein mS33 family.

RefSeq proteins (2): NP_057155, NP_444263* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013219	Ribosomal_mS33	Family

Pfam: PF08293

UniProt features (15 total): helix 6, turn 2, compositionally biased region 2, initiator methionine 1, chain 1, strand 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

77 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7QI4	ELECTRON MICROSCOPY	2.21
8CSS	ELECTRON MICROSCOPY	2.36
7P2E	ELECTRON MICROSCOPY	2.4
8RRI	ELECTRON MICROSCOPY	2.4
9OLF	ELECTRON MICROSCOPY	2.46
9OJM	ELECTRON MICROSCOPY	2.5
8CSQ	ELECTRON MICROSCOPY	2.54
8CSR	ELECTRON MICROSCOPY	2.54
6ZM6	ELECTRON MICROSCOPY	2.59
7QI5	ELECTRON MICROSCOPY	2.63
8CSP	ELECTRON MICROSCOPY	2.66
7PNX	ELECTRON MICROSCOPY	2.76
8ANY	ELECTRON MICROSCOPY	2.85
8CST	ELECTRON MICROSCOPY	2.85
6ZM5	ELECTRON MICROSCOPY	2.89
7PO0	ELECTRON MICROSCOPY	2.9
8K2A	ELECTRON MICROSCOPY	2.9
9PGL	ELECTRON MICROSCOPY	2.9
7PO1	ELECTRON MICROSCOPY	2.92
7PO3	ELECTRON MICROSCOPY	2.92
9PGF	ELECTRON MICROSCOPY	2.93
6VMI	ELECTRON MICROSCOPY	2.96
6RW4	ELECTRON MICROSCOPY	2.97
6VLZ	ELECTRON MICROSCOPY	2.97
7QI6	ELECTRON MICROSCOPY	2.98
8QRN	ELECTRON MICROSCOPY	2.98
9PSM	ELECTRON MICROSCOPY	2.98
8OIS	ELECTRON MICROSCOPY	3
9G5C	ELECTRON MICROSCOPY	3
9G5D	ELECTRON MICROSCOPY	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y291-F1	91.51	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-5368286	Mitochondrial translation initiation
R-HSA-5389840	Mitochondrial translation elongation
R-HSA-5419276	Mitochondrial translation termination
R-HSA-9937383	Mitochondrial ribosome-associated quality control
R-HSA-392499	Metabolism of proteins
R-HSA-5368287	Mitochondrial translation
R-HSA-72766	Translation

MSigDB gene sets: 171 (showing top): GOBP_MITOCHONDRIAL_TRANSLATION, GOBP_TRANSLATION, GOMF_STRUCTURAL_CONSTITUENT_OF_RIBOSOME, GOCC_MITOCHONDRIAL_ENVELOPE, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, WONG_MITOCHONDRIA_GENE_MODULE, ZHANG_BREAST_CANCER_PROGENITORS_UP, ACEVEDO_LIVER_CANCER_UP, GOCC_RIBOSOME, NUYTTEN_EZH2_TARGETS_DN, GOCC_SMALL_RIBOSOMAL_SUBUNIT, GOCC_ORGANELLAR_RIBOSOME, GOCC_MITOCHONDRIAL_MATRIX, GOCC_ORGANELLE_INNER_MEMBRANE, MARSON_BOUND_BY_FOXP3_UNSTIMULATED

GO Biological Process (2): translation (GO:0006412), mitochondrial translation (GO:0032543)

GO Molecular Function (1): structural constituent of ribosome (GO:0003735)

GO Cellular Component (5): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), mitochondrial small ribosomal subunit (GO:0005763), ribosome (GO:0005840), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Mitochondrial translation	4
Translation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidyltransferase activity	1
translational initiation	1
translational elongation	1
translational termination	1
macromolecule biosynthetic process	1
protein metabolic process	1
protein biosynthetic process	1
mitochondrion	1
translation	1
mitochondrial gene expression	1
structural molecule activity	1
ribosome	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
organellar small ribosomal subunit	1
mitochondrial ribosome	1
mitochondrial protein-containing complex	1
intracellular membraneless organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

1708 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MRPS33	NDUFB2	O95178	875
MRPS33	SSBP1	Q04837	822
MRPS33	MRPS18B	Q9Y676	666
MRPS33	MRPL47	Q9HD33	644
MRPS33	MRPS31	Q92665	574
MRPS33	MRPS21	P82921	555
MRPS33	MRPL45	Q9BRJ2	541
MRPS33	NAXE	Q8NCW5	535
MRPS33	MRPL53	Q96EL3	534
MRPS33	RPL8	P25120	487
MRPS33	MRPL50	Q8N5N7	476
MRPS33	MRPL54	Q6P161	475
MRPS33	RPL29	P47914	469
MRPS33	MRPS18A	Q9NVS2	464
MRPS33	NPEPL1	Q8NDH3	458

IntAct

134 interactions, top by confidence:

A	B	Type	Score
MED17	MED19	psi-mi:“MI:0914”(association)	0.840
NDUFS3	NDUFS8	psi-mi:“MI:0914”(association)	0.730
MRPS27	MRPS14	psi-mi:“MI:0914”(association)	0.640
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPL18	NOP56	psi-mi:“MI:0914”(association)	0.530
ZBTB48	ZBTB24	psi-mi:“MI:0914”(association)	0.530
E4F1	ZBTB24	psi-mi:“MI:0914”(association)	0.530
MRPS15	MRPS14	psi-mi:“MI:0914”(association)	0.530
TRMT10B	MRPS14	psi-mi:“MI:0914”(association)	0.530
PDGFB	DKC1	psi-mi:“MI:0914”(association)	0.530
MRPS18B	MRPS14	psi-mi:“MI:0914”(association)	0.530
SNRNP70	GTPBP1	psi-mi:“MI:0914”(association)	0.530
MRPS34	ZZEF1	psi-mi:“MI:0914”(association)	0.530
MRPS18C	MRPS14	psi-mi:“MI:0914”(association)	0.530
MRPS15	PRKACG	psi-mi:“MI:0914”(association)	0.530
MRPS27	YBX1	psi-mi:“MI:0914”(association)	0.530
MRPS26	MRPS10	psi-mi:“MI:0914”(association)	0.530
MRPL18	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MRPL2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MRPS34	MRPS12	psi-mi:“MI:0914”(association)	0.530
MRPS11	MRPS14	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
RPL18	NAP1L1	psi-mi:“MI:0914”(association)	0.530
AURKAIP1	NRDC	psi-mi:“MI:0914”(association)	0.480

BioGRID (199): MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS), MRPS33 (Affinity Capture-MS)

ESM2 similar proteins: A0A0K2GUJ4, A0A1D8PJ73, A3LN78, M9RZ95, O01369, O60169, O74533, P00128, P00129, P0CAB8, P14927, P30815, P33334, P34621, P38231, P46268, P49345, P53733, P82926, P90993, Q04697, Q09375, Q17439, Q22438, Q28GD1, Q54HY7, Q54QG4, Q5ABS1, Q5BJJ8, Q5RC24, Q61SE7, Q6BNL9, Q6BNQ5, Q6C3K7, Q6CTS4, Q6CUZ6, Q6FS31, Q6FSD7, Q6FSJ2, Q6PBR7

Diamond homologs: P82926, Q9D2R8, Q9Y291

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MRPS33	“form complex”	“28S mitochondrial small ribosomal subunit”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 138 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Mitochondrial translation	25	37.0×	3e-31
Mitochondrial ribosome-associated quality control	26	34.3×	3e-31
Mitochondrial translation initiation	25	34.1×	2e-30
Mitochondrial translation elongation	25	34.1×	2e-30
Mitochondrial translation termination	25	29.5×	8e-29
Translation	28	18.7×	1e-26
Peptide chain elongation	7	9.6×	3e-04
Viral mRNA Translation	7	9.6×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
mitochondrial translation	26	35.6×	6e-31
translation	18	14.6×	1e-13
cytoplasmic translation	9	13.1×	7e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	15
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4682694	GRCh37/hg19 7q33-36.3(chr7:137521595-159119707)x1	Pathogenic

SpliceAI

463 predictions. Top by Δscore:

Variant	Effect	Δscore
7:141006381:T:A	donor_gain	1.0000
7:141006347:T:A	donor_gain	0.9900
7:141006435:T:TA	donor_gain	0.9900
7:141006531:CATCT:C	acceptor_gain	0.9900
7:141006533:TCT:T	acceptor_gain	0.9900
7:141006534:CT:C	acceptor_gain	0.9900
7:141006534:CTC:C	acceptor_gain	0.9900
7:141006535:TCT:T	acceptor_gain	0.9900
7:141006536:C:A	acceptor_gain	0.9900
7:141006536:C:CC	acceptor_gain	0.9900
7:141006328:T:TA	donor_gain	0.9800
7:141006535:TC:T	acceptor_loss	0.9800
7:141006536:C:CA	acceptor_loss	0.9800
7:141010393:AGGTC:A	donor_gain	0.9700
7:141006532:ATCT:A	acceptor_gain	0.9600
7:141006540:A:AC	acceptor_gain	0.9600
7:141014912:TAG:T	donor_gain	0.9600
7:141014913:AGA:A	donor_gain	0.9600
7:141006454:C:A	donor_gain	0.9500
7:141010413:CATCA:C	donor_loss	0.9500
7:141010414:ATCAC:A	donor_loss	0.9500
7:141010415:TCAC:T	donor_loss	0.9500
7:141010416:CA:C	donor_loss	0.9500
7:141010417:A:T	donor_loss	0.9500
7:141010418:CCT:C	donor_loss	0.9500
7:141010419:C:G	donor_loss	0.9500
7:141006411:C:CA	donor_gain	0.9200
7:141014820:ATT:A	donor_gain	0.9200
7:141010420:T:C	donor_loss	0.9000
7:141010485:T:C	donor_gain	0.9000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000112170 (7:141013613 C>G), RS1001017135 (7:141007903 C>G), RS1001030070 (7:141008252 AT>A), RS1001065416 (7:141015050 GA>G), RS1001225004 (7:141014375 G>A), RS1001535273 (7:141014767 G>A), RS1001579833 (7:141013125 C>T), RS1001632113 (7:141013488 A>G), RS1001814706 (7:141007488 A>G), RS1001870045 (7:141003097 C>T), RS1001915210 (7:141014829 G>A,T), RS1002278470 (7:141015287 T>C), RS1002577017 (7:141002499 C>T), RS1002800789 (7:141009383 C>A,T), RS1002875093 (7:141004634 C>G)

Disease associations

OMIM: gene MIM:611993 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST003070_2	Cerebrospinal T-tau levels	3.000000e-07
GCST003079_5	Cerebrospinal fluid t-tau:AB1-42 ratio	7.000000e-06
GCST008103_6	Bipolar disorder	6.000000e-10
GCST009600_92	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	5.000000e-09
GCST012465_56	Bipolar disorder	2.000000e-08
GCST90020029_902	Waist circumference adjusted for body mass index	4.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004760	t-tau measurement
EFO:0007708	t-tau:beta-amyloid 1-42 ratio measurement
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression	3
arsenite	decreases methylation, affects binding, increases reaction	2
Acetaminophen	affects cotreatment, decreases expression, increases expression	2
aristolochic acid I	increases expression	1
beta-lapachone	decreases expression	1
manganese chloride	increases abundance, increases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
corosolic acid	decreases expression	1
K 7174	decreases expression	1
bisphenol S	decreases methylation	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic	increases expression, increases abundance	1
Atrazine	decreases expression	1
Vehicle Emissions	decreases methylation	1
Benzo(a)pyrene	decreases methylation	1
Camptothecin	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	decreases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Manganese	increases abundance, increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Selenium	decreases expression	1
Urethane	decreases expression	1
Isotretinoin	decreases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder